What the MHRA Has Said About Mounjaro — and Why It Matters

The most common misconception: MHRA approval means the medicine is freely available

There is a persistent idea that once a medicine clears a regulator, it flows freely onto shelves like a vitamin supplement. With Mounjaro, the opposite is true. MHRA authorisation confirmed that tirzepatide works and is safe enough to prescribe, it did not open an over-the-counter route. The medicine remains a Prescription-Only Medicine under the Human Medicines Regulations 2012, which means a GPhC-registered prescriber must assess you individually before any supply can be made.

This matters practically because a wave of unregulated sellers appeared online after Mounjaro gained its UK licence, marketing pens with no clinical assessment involved. The MHRA has been explicit: buying from such sources is dangerous. In October 2025 the agency raided the first known UK site manufacturing counterfeit tirzepatide, seizing around 20 million doses of illegally traded weight-loss medicines (with an estimated street value of roughly £45 million) across the broader 2025 enforcement campaign. Fake pens have in previous seizures been found to contain insulin rather than the labelled medicine, a potentially fatal mismatch for someone not monitoring blood glucose.

The full Mounjaro overview on this site explains how legitimate private supply works in practice. The short version: prescription first, dispensed by a pharmacy you can verify, delivered in the original manufacturer's packaging.

What the MHRA's Black Triangle designation means for tirzepatide patients

You may have noticed the small inverted triangle printed on Mounjaro packaging or mentioned in the Patient Information Leaflet. That Black Triangle (▼) is an MHRA scheme, applied to newer medicines and vaccines so that healthcare professionals and patients know to report every suspected side effect, not just the unexpected ones. For well-established medicines only new or serious reactions typically need reporting; for Black Triangle products the bar is lower because the post-market safety picture is still being built.

For patients, this is a genuinely useful piece of information rather than a warning sign. It means the regulator is actively watching real-world data, and your report genuinely contributes to that. The Yellow Card scheme at yellowcard.mhra.gov.uk takes about two minutes to complete and can be submitted by anyone, patient, carer or clinician.

If you want to understand the broader clinical picture for tirzepatide (mechanism, strengths, eligibility) the tirzepatide information page covers it clearly with cited sources, and if you are specifically looking into e-Mounjaro, that page explains what it is and how it differs from the standard branded product.

The MHRA's 2026 pancreatitis Drug Safety Update: what changed and what patients should do

In January 2026 the MHRA published a Drug Safety Update specifically addressing acute pancreatitis in people taking GLP-1 medicines including tirzepatide. Pancreatitis is an infrequent but potentially serious side effect: the warning sign to act on is severe, persistent pain in the stomach or abdomen that may radiate through to the back, sometimes accompanied by vomiting. This is not the usual nausea that settles in the first week or two of treatment. If it happens, stop taking the medicine and seek urgent medical attention.

The update did not change prescribing advice in a way that restricts who can be treated, but it reinforced that prescribers should discuss this risk before starting treatment and that patients should not simply wait to see if the pain passes. The NHS patient-level information for tirzepatide lists the full side-effect profile alongside guidance on when to call 111 or go to A&E.

If you are already on treatment and have questions about a symptom, the contact page will reach our support team, who are available seven days a week. For general questions about side effects before starting, the FAQs cover the most common concerns our prescribers hear.

How to check that a Mounjaro supplier is operating inside MHRA and GPhC rules

The practical check takes under a minute. The GPhC (General Pharmaceutical Council) registers every pharmacy legally allowed to dispense prescription medicines in England, Scotland and Wales. Go to the GPhC register at pharmacyregulation.org/registers, search by the pharmacy's name or registration number, and confirm the premises status shows as registered and trading. A seller that cannot be found there should not be supplying prescription medicines. Full stop.

Red flags (beyond a missing GPhC listing) include prices significantly below the market range (Eli Lilly's list price for the highest dose rose to around £330 per four-week pen from September 2025, so sub-£100 offers should prompt immediate scepticism), and sellers advertising Mounjaro without any consultation step. If you are researching specific doses, our pages covering Mounjaro 2.5mg and Mounjaro 5mg set out what to expect at those starting and step-up stages, while our explainer on the Eli Lilly price increase gives market context so you can judge what a realistic private price looks like.

Beyond pharmacy verification, MHRA authorisation of tirzepatide specifically covers the Mounjaro brand supplied by Eli Lilly through the licensed UK supply chain. Pens ordered through informal channels may carry the right label and still contain a different (or no) active substance. The weight-loss treatment overview outlines what a legitimate clinical pathway looks like from start to finish. If you'd like to explore whether treatment is right for you, speak to our prescribers through a free consultation, reviewed the same day by a GPhC-registered Independent Prescriber, not a decision algorithm.